In short
Amgen Inc. (AMGN) has revenue up 10.0% to $36.8B and net income up 88.5% to $7.7B year on year. Its net margin is 21.0%, and it trades at 27.7× trailing earnings. Fisclear flags 1 medium-severity risk and no high-severity ones. How we calculate this
Valuation
HealthcareLive · Yahoo FinancePrice
$435.64
$235.6B
15.7x
2.31%
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Sept 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.88%
Accommodative
10-Year Treasury
5.13%
2026-10-01
Unemployment
4.2%
Near full employment
CPI Index
336.3
2026-09-01
M2 Money Supply
$23.4T
2026-09-01
The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.
SWOT Analysis — AMGN
Inflationary BoomStrengths
Net Income: $7.7B (+88.5% YoY) — Profit grew 89% — the company kept more of each dollar earned.
EPS (Diluted): $14.23 (+88.2% YoY) — Earnings per share rose 88% — each share earned more.
Revenue: $36.8B (+10.0% YoY) — Revenue grew 10% — the company sold more goods or services than the prior year.
Weaknesses
Operating Cash Flow: $10.0B (-13.3% YoY) — Operating cash flow fell 13% but remained positive.
Total Assets: $90.6B (-1.4% YoY) — Total assets shrank 1% — the balance sheet contracted.
Stock is near its 52-week high (482.48) — the price reflects strong recent momentum, but entry risk is elevated at these levels.
Opportunities
No clear opportunities identified at this time.
Threats
Current ratio of 1.14x — thin liquidity buffer against short-term obligations.
Year-over-Year Changes
Net Income
$7.7B
was $4.1B
Profit grew 89% — the company kept more of each dollar earned.
EPS (Diluted)
$14.23
was $7.56
Earnings per share rose 88% — each share earned more.
Operating Cash Flow
$10.0B
was $11.5B
Operating cash flow fell 13% but remained positive.
Revenue
$36.8B
was $33.4B
Revenue grew 10% — the company sold more goods or services than the prior year.
Total Assets
$90.6B
was $91.8B
Total assets shrank 1% — the balance sheet contracted.
Risk Flags
0 high · 1 medium · 1 low- ◈ Medium
Current ratio of 1.14x — thin liquidity buffer against short-term obligations.
- ○ Low
Stock is near its 52-week high (482.48) — the price reflects strong recent momentum, but entry risk is elevated at these levels.
Technical Signals
Daily closes · 1-year dataAmgen Inc.: common questions
Is Amgen Inc. profitable?
Yes. Amgen Inc. made a net profit of $7.7B in its latest fiscal year (fiscal 2025), a net margin of 21.0%.
Is Amgen Inc.'s revenue growing?
Yes. Revenue grew 10.0% year on year, to $36.8B.
What is Amgen Inc.'s P/E ratio?
Amgen Inc. trades at 25.3× its trailing twelve-month earnings. In other words, the share price is about 25 times the profit per share the company earned over the past year.
Does Amgen Inc. pay a dividend?
Yes. Amgen Inc.'s forward dividend yield is 2.31%, the expected annual dividend as a share of the current share price.
What are the main risks for Amgen Inc.?
Fisclear's checks flag 1 medium- or high-severity risk. The most serious: Current ratio of 1.14x — thin liquidity buffer against short-term obligations.
Answers are generated from the figures in this report (updated 5 Nov 2026). Information, not investment advice.
Latest News
via FinnhubFiling History — AMGN
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade AMGN
Links open broker research pages. Not an endorsement or recommendation.
Research Amgen Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.